Prostate Cancer: Most Common Male Cancer
Prostate cancer is the most common cancer in men. PSA screening allows most cases to be detected early. Localized disease has a 10-year survival of 99%. Treatment options: active surveillance, SBRT radiotherapy, brachytherapy, radical prostatectomy (da Vinci robotic), androgen deprivation therapy and Lu-177 PSMA.
SBRT: 5-Session Prostate Cancer Treatment
For localized and low-to-intermediate risk prostate cancer, SBRT has become the gold standard. 5 sessions (typically daily or every other day), total 35-40 Gy. Treatment duration: 1-2 weeks. Over 97% 5-year biochemical control rate. Sexual function and urinary control preservation rates are better than conventional radiotherapy.
FDA-approved Lu-177 PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). 6 IV cycles, improves radiographic PFS by 40%. Combined PSMA PET-CT + treatment at the same center in Istanbul. 2026 expansion to earlier stages expected.
PARP Inhibitors: BRCA Mutation
Olaparib (Lynparza) and Rucaparib are standard for mCRPC with BRCA1/2 or HRR gene mutations. Germline and somatic BRCA/HRR testing is recommended for all prostate cancer patients.
da Vinci Robotic Prostatectomy
da Vinci Xi robotic radical prostatectomy offers better potency and continence outcomes vs open surgery. Less blood loss, faster recovery. Available from experienced uro-oncology surgeons in Istanbul.
SBRT prostate: $6,000-15,000 (USA: $40,000-100,000). Lu-177 6 cycles: $35,000-50,000 (USA: $120,000-200,000). da Vinci prostatectomy: $8,000-18,000 (USA: $30,000-80,000). Savings: 50-83%.